Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Colorectal Cancer Clinical Trial

Official title:

Phase I, Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Colorectal Bioactivity in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01950403
• Other study ID #: MAY2012-00-01
• Secondary ID: NCI-2013-01788HH
• Status: Completed
• Phase: Phase 1
• Start date: September 2013
• Est. completion date: February 22, 2018

Study information

• Verified date: May 2018
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer.

Description:

PRIMARY OBJECTIVES: I. To assess the pharmacodynamic effect (PD) of linaclotide (linaclotide acetate) (single daily dose x 7 days, stage I cohort dose= 0.870 mg/day) on cyclic guanosine monophosphate (cGMP) levels, based on biopsy samples obtained pre- and post-intervention from the rectum, until an effect is documented. SECONDARY OBJECTIVES: I. To confirm the safety and tolerability of linaclotide. II. To assess the pharmacodynamic effect of linaclotide on cGMP levels, analyzed sequentially from the transverse colon to the cecum, if no cGMP effect was observed in the rectum for the primary endpoint. III. To compare the change in the cGMP levels from baseline to day 7 between all the assigned doses of linaclotide (including placebo), analyzed sequentially from the rectum, transverse colon, and cecum. IV. If the study proceeds to stage II, the pharmacodynamic effect of linaclotide on cGMP levels will be assessed from day 6 rectal biopsies (un-prepped). TERTIARY OBJECTIVES: I. To assess the pharmacodynamic effect of linaclotide on an additional pathway-specific biomarkers relevant to guanylate cyclase C (GCC) signaling (i.e., vasodilator-stimulated phosphoprotein [VASP] phosphorylation) and a marker of general proliferation (Ki67 expression), based on intestinal mucosa biopsy samples obtained by colonoscopy pre- and post-exposure at the anatomical location (rectum, transverse colon, or cecum) in which cGMP is elevated following linaclotide exposure. OUTLINE: This is a dose-escalation study. Participants are randomized to 1 of 2 treatment arms. ARM I: Participants receive linaclotide acetate orally (PO) once daily (QD) on days 1-7. ARM II: Participants receive placebo PO QD on days 1-7. After completion of treatment, participants are followed up for 21-51 days.

Other known NCT identifiers

• NCT01912079

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: February 22, 2018
• Est. primary completion date: April 28, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• PRE-REGISTRATION INCLUSION CRITERIA
• Ability to understand and willingness to sign a written informed consent document and follow study procedures
• Willingness to abstain from grapefruit juice, alcohol, and concomitant medications during study
• Willingness to employ adequate contraception for men and women of childbearing potential; acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status documented by serum follicle-stimulating hormone (FSH), and/or documentation of surgical sterilization
• Body mass index < 35 kg/m^2
• Willingness to provide blood and tissue specimens for research purposes
• REGISTRATION INCLUSION CRITERIA
• Participants must have normal organ function and have normal laboratory findings without clinically significant findings
• Satisfactory anesthesia and intestinal preparation, with no findings of advanced adenoma, chronic inflammation, or cancer

Exclusion Criteria:

• PRE-REGISTRATION EXCLUSION CRITERIA
• Previous personal history of advanced adenomas (>= 1 cm in maximal diameter, >= 3 in total number, villous morphology, or high-grade dysplasia) or colorectal cancer
• Family history of polyposis syndrome (e.g., familial adenomatous polyposis [FAP], hereditary non-polyposis colorectal cancer [HNPCC]) or colorectal cancer (first degree relatives younger than 60 years old)
• History of gastroparesis
• History of surgery involving the luminal gastrointestinal (GI) tract, including bariatric surgery
• History of celiac disease
• Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
• Irritable bowel syndrome, chronic constipation, functional bowel disorders, or colonic motility disorder
• Any malignancy within 3 years of baseline; participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator
• Participants may not be receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide
• History of difficulty with colonoscopy or abnormal colorectal anatomy
• Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or lactating women
• Use of laxatives more than 3 times per week
• Intestinal motility agents, histamine-2 inverse agonists (H-2 blockers), or proton pump inhibitors
• Current use of >= 5 cigarettes/day
• Current use of >= 3 alcoholic drinks/day
• Use anti-platelet agents within two weeks of anticipated colonoscopy
• Use of anti-coagulants within two weeks of anticipated colonoscopy
• History of bleeding/coagulation problems
• Prior intolerance of or contraindications for the use of sedation or anesthetic agents, which would prevent the safe use of sedation for colonoscopy; this includes allergies to eggs and soy products
• Any medical condition judged by the investigator to constitute a risk to safe participation
• REGISTRATION EXCLUSION CRITERIA
• Colonoscopic finding requiring clinical intervention
• Use of any illicit or illegal substances detected by urinary drug screen
• Inadequate pre-intervention bowel preparation, as determined by the study physician

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Healthy, no Evidence of Disease

Intervention

Drug:
• linaclotide acetate
Given PO

Other:
• placebo
Given PO
• pharmacological study
Correlative studies
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PD effect of linaclotide acetate on GCC signaling (i.e., VASP phosphorylation) and general proliferation (Ki67 expression)	Summary statistics, frequency tables, non-parametric tests, and graphical methods will be used to describe the distributions of cGMP levels relative to linaclotide acetate dose levels and biomarkers. Linear and logistic regression models may also be used as appropriate.	Up to 7 days
Primary	Dose of linaclotide acetate that produces a 60% response rate for cGMP levels in rectal tissue by radioimmunoassay (RIA)	The pharmacological effect is measured by the arithmetic difference in mean cGMP levels before and after 7 days of linaclotide acetate in biopsies from the colonoscopy. The mean cGMP value will be calculated based on 2 biopsies from the rectum assessed at each time point. The PD response is measured by the difference in mean cGMP levels after 7 days.	Baseline to 7 days
Secondary	Incidence of adverse events associated with linaclotide acetate assessed using the Common Terminology Criteria for Adverse Events version 4.0	Summary statistics, frequency tables, and non-parametric tests will be used to describe the distributions of adverse events.	Up to 51 days
Secondary	PD effect of linaclotide acetate on cGMP levels from the transverse colon to the cecum		Up to 7 days
Secondary	Change in cGMP levels between all assigned doses, analyzed sequentially from the rectum, transverse colon, and cecum	Summary statistics and nonparametric tests will be used to compare the change in the cGMP levels between the different dose levels of linaclotide acetate and placebo.	Baseline to 7 days
Secondary	PD effect on cGMP levels (Stage II)	Changes in cGMP levels from baseline to day 6 will also be assessed using summary statistics and nonparametric tests.	Up to 6 days